- Conditions
- Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Pacific Eye Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 669
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 53
- States / cities
- Mesa, Arizona • Sun City, Arizona • Campbell, California + 49 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Faricimab, Sham Procedure, Anti-VEGF Therapy
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,036 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 85
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Streetlab VR
- Diagnostic Test
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- REGN2176-3, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
- Conditions
- Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
- Interventions
- i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
- Device
- Lead sponsor
- i-Lumen Scientific, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- verteporfin, ranibizumab, dexamethasone
- Drug
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- APL-2, Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
- Conditions
- Geographic Atrophy
- Interventions
- RO7171009
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Bakersfield, California • Mountain View, California • Sacramento, California + 10 more
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Fluocinolone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Aged Macular Degeneration
- Interventions
- Omega 3, Olive Oil
- Dietary Supplement · Other
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- 20 Years to 49 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Geographic Atrophy of the Macula
- Interventions
- GAL-101, Placebo
- Drug
- Lead sponsor
- Galimedix Therapeutics Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
- Conditions
- Cataract, Macular Degeneration
- Interventions
- selenium, vitamin E, vitamin E placebo, selenium placebo
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 50 Years to 120 Years · Male only
- Enrollment
- 13,475 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- All participants
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 18,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire
- Conditions
- Macular Edema, Macular Degeneration
- Interventions
- Ranibizumab
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Retina Center, Minnesota
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AM712(ASKG712)
- Biological
- Lead sponsor
- AffaMed Therapeutics Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Poway, California • Walnut Creek, California • Lakewood, Colorado + 6 more